Description of the main functions and efficacy of Tepotinib/Tudekan

Tepotinib is a targeted therapy drug specifically used to treat patients with non-small cell lung cancer (NSCLC) carrying MET gene exon 14 skipping mutations. MET gene exon 14 skipping mutation is a specific gene mutation in non-small cell lung cancer, which is usually associated with disease progression and recurrence, and is relatively resistant to traditional treatments.

1. Main mechanism of action:

Tepotinib is aMET inhibitor that blocks cell signaling pathways related to MET gene mutations by targeting and inhibiting the activity of MET tyrosine kinase. This inhibitory effect helps reduce the proliferation and spread of tumor cells, thereby effectively slowing or stopping the progression of lung cancer. Tepotinib provides a precise treatment method that can reduce damage to normal cells by selectively acting on MET-mutated tumor cells.

2. Treatment effect:

Clinical studies have shown that tepotinib has shown significant efficacy in the treatment of MET exon 14 skipping mutation non-small cell lung cancer. Especially after patients have received other treatments, tepotinib has shown a good therapeutic response. For patients whose traditional chemotherapy and immunotherapy are ineffective, tepotinib provides a new treatment option and improves the patient's quality of life and prognosis.

3. Indications:

Tepotinib is mainly used to treat patients with unresectable, progressive and recurrent non-small cell lung cancer who carryMET gene exon 14 skipping mutations. It provides a new targeted treatment option for patients with advanced non-small cell lung cancer who have responded poorly to other therapies. The drug has been approved in many countries and regions, and has shown its therapeutic effect on MET gene mutation-related non-small cell lung cancer in multiple clinical studies. By precisely targeting MET mutations, tepotinib provides patients with a more personalized treatment plan, reducing side effects and drug resistance problems during treatment.

Keyword tags: Tepotinib,Tepotinib, MET gene exon 14 skipping mutation, non-small cell lung cancer, targeted therapy, cancer treatment, lung cancer drugs, MET inhibitors, therapeutic effect

Reference materials:https://www.tepmetko.com/us-en/home.html